Ctic stock earnings
WebStock is heavily short : 20% of float is short 80% Institutional investors. nice swing opportunity for a re-bounce to the upper "resistance" channel line. NASDAQ:CTIC Stock had decent drop right after earnings to the lowest channel support line. Stock is heavily short : 20% of float is short 80% Institutional investors. WebApr 10, 2024 · The equity awards were approved on April 10, 2024, in accordance with Nasdaq Listing Rule 5635 (c) (4). The employees received options to purchase an …
Ctic stock earnings
Did you know?
WebStock Quote. Change Volume 52 Week High 52 Week Low Apr 13, 2024 1:41 PM EDT. Data Provided by Refinitiv. ... Wash. , April 12, 2024 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today … WebCTI BioPharma Corp. analyst ratings, historical stock prices, earnings estimates & actuals. CTIC updated stock price target summary.
WebThe Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingSep 2024 , … WebApr 10, 2024 · CTI BioPharma (CTIC) delivered earnings and revenue surprises of -55.56% and 15.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock? 1 month ago - Zacks Investment Research
WebAug 1, 2024 · Get the latest CTI BioPharma Corp. (CTIC) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. ... Financials Dividends Adv. Charts Earnings Options ...
WebCTIC Stock Price - CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. ... The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the ...
WebApr 10, 2024 · CTIC Stock Overview. CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. ... Earnings-US$92.99m: Last Reported Earnings. Dec 31, 2024. Next Earnings Date. n/a. Earnings per share (EPS)-0.71: … georgia law window tintWebApr 10, 2024 · Insiders have sold a total of 8,266,741 CTI BioPharma shares in the last 24 months for a total of $50,565,290.56 sold. This page (NASDAQ:CTIC) was last updated on 4/8/2024 by MarketBeat.com Staff. Get 30 Days of MarketBeat All Access Free. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: christian marsollierWeb2 days ago · Get the latest CTI BioPharma Corp CTIC detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP ... georgia lawyers listWeb1 day ago · • Regarding CTIC CTIC, we observe a call option trade with bullish sentiment. It expires in 65 day(s) on June 16, 2024 . Parties traded 3000 contract(s) at a $5.00 strike. christian marshWebCTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates. CTI BioPharma (CTIC) delivered earnings and revenue surprises of -55.56% and 15.24%, respectively, for the quarter ended December 2024 ... georgia lawyers pro bonoWebApr 10, 2024 · SEATTLE, April 10, 2024 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of … georgia leadership certificationWebStock CTIC . Posted: Apr 12 2024, 16:30. Author Name: PRNewsWire. Views: 041225. CTIC News . By PRNewsWire April 12, 2024. CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2024 ... CTI BioPharma (CTIC) delivered earnings and revenue surprises of -55.56% and 15.24%, respectively, for the quarter ended … christian marshall